Literature DB >> 24585545

Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets.

Gina Y Kim1, Ana Gabrea, Yulia N Demchenko, Leif Bergsagel, Anna V Roschke, W Michael Kuehl.   

Abstract

Primary IGH translocations involving seven recurrent partner loci and oncogenes are present in about 40% of multiple myeloma tumors. Secondary IGH rearrangements, which occur in a smaller fraction of tumors, usually are complex structures, including insertions or translocations that can involve three chromosomes, and often with involvement of MYC. The main approach to detect IGH rearrangements is interphase-but sometimes metaphase-FISH strategies that use a telomeric variable region probe and a centromeric constant region/ Eα enhancer or 3' flanking probe to detect a separation of these two probes, or a fusion of these probes with probes located at nonrandom partner sites in the genome. We analyzed 18 myeloma cell lines for detection discrepancies among Vysis, Cytocell, and in-house IGH probe sets that hybridize with differing sequences in the IGH locus. There were no detection discrepancies for the three telomeric IGH probes, or for unrearranged IGH loci or primary IGH translocations using the centromeric IGH probes. However, the majority of complex IGH rearrangements had detection discrepancies among the three centromeric IGH probes.
Copyright © 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24585545      PMCID: PMC4011190          DOI: 10.1002/gcc.22158

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  18 in total

1.  Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell.

Authors:  A Gabrea; P L Bergsagel; M Chesi; Y Shou; W M Kuehl
Journal:  Mol Cell       Date:  1999-01       Impact factor: 17.970

2.  A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies.

Authors:  G J Ahmann; S M Jalal; A L Juneau; E R Christensen; C A Hanson; G W Dewald; P R Greipp
Journal:  Cancer Genet Cytogenet       Date:  1998-02

3.  Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma.

Authors:  F M Ross; A H Ibrahim; A Vilain-Holmes; M O Winfield; L Chiecchio; R K M Protheroe; P Strike; J L Gunasekera; A Jones; C J Harrison; G J Morgan; N C P Cross
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

4.  Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma.

Authors:  L Chiecchio; R K M Protheroe; A H Ibrahim; K L Cheung; C Rudduck; G P Dagrada; E D Cabanas; T Parker; M Nightingale; A Wechalekar; K H Orchard; C J Harrison; N C P Cross; G J Morgan; F M Ross
Journal:  Leukemia       Date:  2006-07-06       Impact factor: 11.528

Review 5.  Distinguishing primary and secondary translocations in multiple myeloma.

Authors:  Ana Gabrea; P Leif Bergsagel; W Michael Kuehl
Journal:  DNA Repair (Amst)       Date:  2006-07-10

6.  Arrangement of human immunoglobulin heavy chain constant region genes implies evolutionary duplication of a segment containing gamma, epsilon and alpha genes.

Authors:  J G Flanagan; T H Rabbitts
Journal:  Nature       Date:  1982-12-23       Impact factor: 49.962

7.  The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.

Authors:  Lucía López-Corral; Norma C Gutiérrez; Maria Belén Vidriales; Maria Victoria Mateos; Ana Rasillo; Ramón García-Sanz; Bruno Paiva; Jesús F San Miguel
Journal:  Clin Cancer Res       Date:  2011-02-16       Impact factor: 12.531

Review 8.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

9.  Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.

Authors:  Ana Gabrea; Maria Luisa Martelli; Ying Qi; Anna Roschke; Bart Barlogie; John D Shaughnessy; Jeffrey R Sawyer; W Michael Kuehl
Journal:  Genes Chromosomes Cancer       Date:  2008-07       Impact factor: 5.006

10.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

View more
  1 in total

1.  Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers.

Authors:  Jonathan N Hofmann; Laura E Beane Freeman; Kazunori Murata; Gabriella Andreotti; Joseph J Shearer; Katie Thoren; Lakshmi Ramanathan; Christine G Parks; Stella Koutros; Catherine C Lerro; Danping Liu; Nathaniel Rothman; Charles F Lynch; Barry I Graubard; Dale P Sandler; Michael C Alavanja; Ola Landgren
Journal:  Environ Health Perspect       Date:  2021-01-06       Impact factor: 11.035

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.